GammaTile by GT Medical Technologies, Inc.

The GammaTile team is pleased to announce the interim results of the Phase 3 Randomized Controlled Trial, which were recently presented at the 2025 Congress of Neurological Surgeons Annual Meeting. The study found that GammaTile reduced the risk of tumor recurrence or death by more than 50% compared to standard of care (surgery followed by delayed stereotactic radiation). Importantly, these gains were achieved without any increase in treatment-related side effects, reinforcing the safety and efficacy of immediate, targeted radiation delivered at surgery.(1) The findings represent a significant step forward in brain metastasis care and highlight the growing impact of GammaTile in improving patient outcomes. Together, we’re changing what’s possible for patients with brain tumors, delivering immediate radiation when and where it is needed most. Read the press release to learn more: tinyurl.com/8mpnavwj This interim analysis is based on data from 168 of the 230 patients enrolled in the study. Randomization was conducted on a 1:1 basis. All results presented are preliminary and subject to change as additional data become available from the remaining enrolled participants. REFERENCE: Weinberg J, Beckham TH, Lin H, et al. Interim analysis of a phase 3 randomized controlled trial for treatment of newly diagnosed metastatic brain tumors(ROADS, NCT04365374).

Brain Tumor Awareness Month wraps up this week, but not before a final clinical spotlight on recurrent meningioma. This prospective, multi-center observational study demonstrates that resection and GammaTile for aggressive, recurrent meningiomas resulted in encouraging local control and low adverse event rate. Check back in tomorrow to hear from neurosurgeon Joseph Zabramski, MD, about how GammaTile fits into the treatment plan for recurrent meningioma. Read the abstract: na2.hubs.ly/H05LcxF0 #BrainTumorAwarenessMonth #BTAM #GammaTile #RecurrentMeningioma REFERENCE: Desai B, et al. Neuro-Oncology. 2025;27(Suppl 5):v107. See full prescribing information at na2.hubs.ly/H05LcHT0

ASCO 2026 is right around the corner! Join the GammaTile team this Saturday for “Results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.” Learn more: na2.hubs.ly/H05LcBj0 Not attending ASCO? Sign up to see the data once released: na2.hubs.ly/H05Lf-y0 See full prescribing information at na2.hubs.ly/H05LhYQ0

Learn more about BRIDGES, our phase 3 randomized trial of immediate postoperative cesium-131 tile-based radiation therapy followed by abbreviated chemoradiation for newly diagnosed glioblastoma, at the American Society of Clinical Oncology Annual Meeting. View the poster from 1:30-4:30 CDT in Hall A on Monday, June 1st. We hope to see you there! Learn more: na2.hubs.ly/H05J2qD0 See full prescribing information at na2.hubs.ly/H05J1l40

Join the GammaTile team for a presentation at the American Society of Clinical Oncology titled “Outcomes of a feasibility and safety trial of tile-based radiation therapy with cesium-131 followed by external beam radiation therapy with concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma.” Learn more: na2.hubs.ly/H05J0KP0 See full prescribing information at na2.hubs.ly/H05J1xH0

In a prospective, multi-institutional study examining the efficacy of GammaTile for the treatment of recurrent brain metastases, cumulative incidences of local failure per-patient at 6, 12, and 15 months were 11.7%, 18.4%, and 22.5%, respectively. This analysis demonstrates encouraging outcomes with GammaTile for salvaging previously irradiated, recurrent brain metastases after prior radiotherapy. Read the abstract: na2.hubs.ly/H05HqL30? #RecurrentBrainMetastases #BrainMets #GammaTile REFERENCE: Kotecha R, et al. Neuro-Oncology. 2025;27(Suppl 5):v104. See full prescribing information at na2.hubs.ly/H05Hr7s0

Join us at the American Society of Clinical Oncology Annual Meeting on Saturday, May 30th, to hear the “Final results of a randomized, controlled, phase 3 trial comparing resection and post-operative stereotactic radiation versus resection and cesium-131 tile-based radiation for treatment of newly diagnosed brain metastases.” Learn more: na2.hubs.ly/H05HfFR0 Not attending ASCO? Sign up to see the data once released: na2.hubs.ly/H05HfhF0 See full prescribing information at na2.hubs.ly/H05HffT0

“The ability to deliver immediate, localized radiation therapy at the time of surgery helps to avoid delays, reduces reliance on post-operative radiosurgery, and mitigates the overall cumulative toxicity,” says Radiation Oncologist Rupesh Kotecha, MD. In this prospective, multi-institutional study, Dr. Kotecha examined the efficacy of GammaTile for the management of patients with recurrent brain metastases. The analysis demonstrated encouraging outcomes with GammaTile for treating previously irradiated, recurrent brain metastases. Read the abstract: na2.hubs.ly/H05DXj40? Dr. Kotecha is the Chief of Radiosurgery in the Department of Radiation Oncology and Director of the Central Nervous System Metastasis program at Miami Cancer Institute. #RecurrentBrainMetastases #BrainMets #GammaTile #BrainTumorAwarenessMonth Quotes are based on the personal experience and learnings of the featured healthcare professionals. REFERENCE: Kotecha R, et al. Neuro-Oncology. 2025;27(Suppl 5):v104. See full prescribing information at na2.hubs.ly/H05DXfm0

We’re halfway through Brain Tumor Awareness Month and this week’s focus is on clinical data supporting GammaTile’s use in the treatment of recurrent brain metastases. This prospective, multi-institutional study showed encouraging outcomes with GammaTile for salvaging previously irradiated, recurrent brain metastases after prior radiotherapy across 19 different centers with a low cumulative incidence rate of local failure and adverse radiation effects. Tune in tomorrow to hear from one of the study’s authors, Dr. Rupesh Kotecha. Read the abstract: na2.hubs.ly/H05D5WY0? #RecurrentBrainMetastases #BrainMets #GammaTile #BrainTumorAwarenessMonth REFERENCE: Kotecha R, et al. Neuro-Oncology. 2025;27(Suppl 5):v104. See full prescribing information at na2.hubs.ly/H05D2cv0

Yesterday, Neurosurgeon Dr. Matthew J. Shepard discussed his insights on the key findings of the prospective registry study published in the Journal of Neuro-Oncology. Among those key findings, authors reported a 92.3% local control rate at 12 months. #BrainTumorAwarenessMonth #NewlyDxBrainMets #BrainMetastases #GammaTile REFERENCE: Kite T, Hanft S, Zeller S, et al. J Neurooncol. 2026;176(3):199. See full prescribing information at na2.hubs.ly/H05vdV60

Matthew J. Shepard, MD, neurosurgeon and corresponding author of a prospective registry study, found that for patients with newly diagnosed brain metastases treated with GammaTile, local control rates were high and rates of leptomeningeal disease were modest. In a conversation about the study, Dr. Shepard shared his insights on the importance of eliminating the gap between surgery and radiation. Read the abstract: na2.hubs.ly/H05tq0t0 Dr. Shepard is an Assistant Professor of Neurosurgery at Drexel University College of Medicine and serves as the Director of Brain Tumor Research within the Allegheny Health Network’s Neuroscience Institute. #BrainTumorAwarenessMonth #NewlyDxBrainMets #BrainMetastases #GammaTile Quotes are based on the personal experience and learnings of the featured healthcare professionals. REFERENCE: Kite T, Hanft S, Zeller S, et al. J Neurooncol. 2026;176(3):199. See full prescribing information at na2.hubs.ly/H05tptb0

To close out National Nurses Week, we’re proud to spotlight GammaTile Territory Manager and Registered Nurse Chelsea Elwer. Listen as she shares why advocating for the expansion of GammaTile to patients with operable brain tumors is at the heart of her work. #NationalNursesWeek #GammaTile #BrainTumorAwarenessMonth See full prescribing information at na2.hubs.ly/H05rKrr0

This week's Brain Tumor Awareness Month clinical data highlights will focus on newly diagnosed brain metastases. In this prospective registry study, GammaTile at the time of resection of newly diagnosed brain metastases was associated with high rates of tumor control and modest rates of leptomeningeal disease. Tune in tomorrow to hear from the study’s corresponding author, Dr. Matthew J. Shepard. Read the abstract: na2.hubs.ly/H05rwJ50 #BrainTumorAwarenessMonth #NewlyDxBrainMets #BrainMetastases #GammaTile REFERENCE: Kite T, Hanft S, Zeller S, et al. J Neurooncol. 2026;176(3):199. See full prescribing information at na2.hubs.ly/H05rwRj0

In honor of National Nurses Week, we turned to the nurses we are proud to have on our team at GammaTile. We asked them, "How has your experience as a nurse impacted your approach to your work with GammaTile?" From clinical research to field sales, our team members with nursing backgrounds bring a level of patient-first thinking that shapes their positions now. Their clinical backgrounds don't just inform their expertise, but fuel a deeper commitment to the physicians and patients who depend on GammaTile every day. #NationalNursesWeek #GammaTile #BrainTumorAwarenessMonth See full prescribing information at na2.hubs.ly/H05qsk50

Happy National Nurses Week! We’re proud to recognize the talented professionals who bring expertise and empathy to every patient they serve. Hear from Registered Nurse and GammaTile Territory Manager Melissa McKendrick-Marano about her start in the medical field as an oncology nurse and how that has impacted her work with GammaTile. Thank you to Melissa and all of the other hardworking nurses in the brain tumor community! #NationalNursesWeek #GammaTile #BrainTumorAwarenessMonth See full safety information at na2.hubs.ly/H05nmnb0

Yesterday, Radiation Oncologist M. Sean Peach, MD, PhD, shared what he thinks GammaTile’s role is in the treatment of recurrent grade IV glioma. Here's the clinical evidence behind his perspective. Results from a multicenter prospective cohort study evaluating GammaTile in patients with recurrent Grade IV gliomas reported 6- and 12-month progression-free survival rates of 74.6% and 56.6%, with local control at 91.8% and 87.7%, respectively. These results support further investigation of GammaTile as part of a multimodal treatment strategy for recurrent glioblastoma. Read the abstract: na2.hubs.ly/H05lQdJ0 #BrainTumorAwarenessMonth #RecurrentGBM #Glioblastoma #GammaTile REFERENCE: Peach MS, et al. Neuro Oncol. 27(suppl 5):v109-v110 (2025). See full prescribing information at na2.hubs.ly/H05lPP20

In recognition of Brain Tumor Awareness Month, we are dedicating this week to glioma clinical education. Hear from Radiation Oncologist M. Sean Peach, MD, PhD, on where he believes GammaTile fits into the treatment algorithm for recurrent grade IV glioma: na2.hubs.ly/H05kGzC0 Dr. Peach is the lead author on the study “Surgically Targeted Radiation Therapy for Recurrent Grade IV Gliomas: Initial Results from a Multicenter Prospective Cohort Study.” #BrainTumorAwarenessMonth #RecurrentGBM #Glioblastoma #GammaTile REFERENCE: Peach MS, et al. Neuro Oncol. 27(suppl 5):v109-v110 (2025). See full prescribing information at na2.hubs.ly/H05kGtg0

This Brain Tumor Awareness Month, we're dedicating each week in May to a different tumor type, highlighting clinical evidence that demonstrates how GammaTile consistently delivers outcomes that matter for patients with operable brain tumors. This week's focus is gliomas, including glioblastoma. In this week’s featured study, authors concluded that GammaTile was well-tolerated, showing promising survival and local control outcomes, with median survival from STaRT exceeding published operative series.(1) Read the abstract: na2.hubs.ly/H05j8Lt0 Check back in tomorrow to hear from the study’s lead author, Dr. M. Sean Peach. #BrainTumorAwarenessMonth #RecurrentGBM #Glioblastoma #GammaTile REFERENCE: Peach MS, et al. Neuro Oncol. 27(suppl 5):v109-v110 (2025). See full prescribing information at na2.hubs.ly/H05j8r_0